Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
出版年份 2011 全文链接
标题
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
作者
关键词
-
出版物
CANCER
Volume 117, Issue 23, Pages 5351-5358
出版商
Wiley
发表日期
2011-05-17
DOI
10.1002/cncr.26188
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
- (2015) Véronique Mathieu et al. NEOPLASIA
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
- (2010) Richard M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
- (2009) Gigi Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of salvage reirradiation for malignant gliomas that progress on bevacizumab
- (2009) Roy G. Torcuator et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
- (2009) F. M. Iwamoto et al. NEUROLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme
- (2008) Jeannette R. Flynn et al. CANCER
- Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial
- (2008) Andreas Hermes et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
- (2008) Marta Santisteban et al. JOURNAL OF NEURO-ONCOLOGY
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
- Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model
- (2008) Kristoph Jahnke et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started